AUTHORS
Liron Hofstetter, MD, Pia Raanani, MD2, Alena Kirzhner, MD`3, Ramon Cohen, MD4
AFFILIATIONS
1 Institute of Hematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
2 Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel, Institute of Hematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
3 Hebrew University of Jerusalem, Jerusalem, Israel, Kaplan Medical Center, Rehovot, Israel
4 Hebrew University of Jerusalem, Jerusalem, Israel, Kaplan Medical Center, Rehovot, Israel
ABSTRACT
Background:
Chronic lymphocytic leukemia (CLL) predominantly affects older adults, a population at increased risk of osteoporosis and fragility fractures. CLL may further contribute to skeletal fragility through disease-related alterations in the bone microenvironment and bone remodeling. However, the incidence and clinical impact of osteoporosis and fragility fractures in patients with CLL have not been well defined at the population level. We therefore aimed to evaluate the incidence of osteoporosis and fragility fractures in a large population-based matched cohort of patients with CLL.
Materials and Methods:
We conducted a retrospective population-based cohort study using electronic health records from Clalit Health Services, a nationwide health maintenance organization. Patients aged 50–80 years with diagnosed CLL between 2005 and 2025 were identified and matched 1:1 to CLL-free controls by age, sex, smoking status, underweight status, alcohol use, proton pump inhibitor exposure, diabetes, chronic kidney disease, and corticosteroid exposure. Patients with previous osteoporosis or fragility fracture were excluded from the primary cohort. Fragility fracture was defined as hip, vertebral, or wrist fracture. Several additional matched-cohort designs were used. We also generated a cohort of CLL patients who had never received treatment and were matched on prior fall history to control for baseline frailty.
A second design examined fracture risk among patients with osteoporosis, comparing those with versus those without CLL, matching for bisphosphonate use before CLL diagnosis and excluding all corticosteroid-exposed patients.
Outcomes were analysed separately by sex using Kaplan–Meier estimates and cumulative incidence (CI) functions, with death as a competing risk.
Results:
The primary analysis included 3,469 patients in each group with balanced baseline characteristics. CLL was associated with a higher incidence of fragility fractures in both sexes. Among women, this excess remained significant after accounting for competing mortality (competing-risk p=<0.01), with an estimated 10-year CI of approximately 15.7% in CLL patients compared with 9.1% in matched controls. In men, fracture incidence was also higher among CLL patients (approximately 7.5% vs. 6.5% at 10 years), reaching significance using conventional censoring analysis (p=0.015) but attenuating after death as competing-risk adjustment (p=0.3). Osteoporosis incidence in CLL vs. control was numerically higher among CLL patients; however, statistical significance was observed only in men using standard censoring analysis (p=0.019) and was lost after competing-risk adjustment. When we examined fractures and osteoporosis in patients who survived 4 years after CLL diagnosis, statistical significance was observed in both sexes for fractures and osteoporosis diagnoses (P<0.001) in both conventional and competing risk analyses.
Among patients with established osteoporosis, CLL diagnosis was associated with a significantly increased risk of subsequent fragility fracture compared to controls without CLL. This excess remained significant after accounting for competing mortality in both men (p<0.02; estimated 10-year CI approximately 21–22% vs. 12%) and women (p < 0.01; approximately 13.8% vs. 7%).
There was no difference in fractures or osteoporosis between the untreated CLL cohort and the matched control cohort.
Conclusions:
CLL is associated with increased fragility fracture risk with distinct sex-specific patterns. Women demonstrate a fracture excess, independent of competing mortality, and frequently occurring without prior osteoporosis diagnosis. In men, risk becomes evident mainly after osteoporosis diagnosis and among long-term survivors. These findings highlight the need for proactive, sex-tailored bone health surveillance strategies in patients with CLL.
DISCLOSURES
Liron Hofstetter, MD: AstraZeneca - Honoraria; AbbVie - Honoraria; Johnson & Johnson - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony)